|
| | 
|
 | |
         
|  |
|  |
|
Mostrar Noticias: Ver noticias de otros activosBúsqueda de noticias relacionadas a la acción Forest Laboratori (ordenadas por fecha):
|
Zacks Reaffirms Neutral Rating on Forest Laboratories (FRX)Junction ReportForest Laboratories (NYSE: FRX)'s stock had its ?neutral? rating reiterated by Zacks in a note issued to investors on Monday. They currently have a $37.00 target price on the stock. Zacks' analyst wrote, ?Forest Labs is facing tough times with its lead ...y más » |
|
Auriga Initiates Coverage on Forest Laboratories (FRX)Daily PoliticalInvestment analysts at Auriga began coverage on shares of Forest Laboratories (NYSE: FRX) in a note issued to investors on Thursday. The firm set a ?hold? rating and a $36.00 price target on the stock. Shares of Forest Laboratories traded up 0.78% ... |
|
Earnings Scorecard: Forest LabsZacks.comFollowing the release of fourth quarter and fiscal 2012 results, most of the analysts covering Forest Laboratories (FRX - Analyst Report) have made downward revisions to their earnings estimates for fiscal 2013. The downward revision in estimates is ...y más » |
|
ThinkEquity Raises Price Target on Forest Laboratories (FRX)Daily PoliticalInvestment analysts at ThinkEquity lifted their target price on shares of Forest Laboratories (NYSE: FRX) to $40.00 in a note issued to investors on Tuesday. The firm currently has a ?buy? rating on the stock. Forest Laboratories traded down 0.69% on ... |
|
M&A: Four Health Care Stocks in Play (AMLN, FRX, STJ, EW)Stock Traders DailyAnother drugmaker that may soon find itself to be the subject of an increasing number of takeover rumors is Forest Laboratories (NYSE: FRX). The company has been mentioned as a potential target for AstraZeneca (NYSE: AZN) as AstraZeneca begins its ...y más » |
|
Synergy Pharmaceuticals (NASDAQ:SGYP) May Be Ready To RollMarket PlaygroundIronwood, for example, already has a partner in Forest Laboratories, Inc. (NYSE:FRX), which takes them, for the most part, out of the equation as a potential buyout candidate by a deep-pocketed third party who would have to purchase two companies to ...y más » |
Forbes |
Best Summer Stocks And BooksForbesDrugmaker Forest Laboratories (FRX, 34) has a checkered past?too much of one big patent-expired antidepressant (Lexapro)?and 2010 criminal settlements and allegations. That's all in the past. The future is brighter with a great stream of 17 new and ... |
|
Cancer Tools Help Roche Push Ahead With Alzheimer's DrugBusinessWeekThe last new therapy for Alzheimer's was Namenda, a medicine from New York-based Forest Laboratories Inc. (FRX) (FRX) approved in 2003, according to data compiled by Bloomberg. Namenda, like all other Alzheimer's drugs on the market, addresses symptoms ...y más » |
|
Elevation boasts "gold standard" IIb data for COPD therapyFierceBiotechForest ($FRX) enjoyed an upbeat FDA panel review for its contender, aclidinium (licensed from Almirall), back in February. And Pearl Therapeutics has its own promising mid-stage program. None of the competition, though, has deterred Elevation's venture ...y más » |
|
2 Strong Pharmaceuticals To Consider Now, 1 To AvoidSeeking AlphaForest Laboratories (FRX) is a mid-sized pharmaceutical on the verge of shrinking itself to oblivion. The company recorded annual revenues of over $4 billion in 2010. This year, it will be lucky to achieve half that revenue. Its lead drug, Lexapro, ... |
|
Private equity firms snap up 50% of RottapharmFiercePharmaAmong the potential investors that walked away were Mylan ($MYL), Forest Pharmaceuticals ($FRX), and Watson Pharmaceuticals ($WPI). Earlier this year, Reuters reported that price was the sticking point, provided the Rovatis insisted on keeping control ...y más » |
|
Beaten-up AstraZeneca may be a buy for the braveReuters UKO) or larger specialist drugmaker Forest Laboratories (FRX.N). But analysts at Liberum Capital believe AstraZeneca could still acquire the latter for around $10 billion without disrupting expected cash returns. Bigger buys like Shire (SHP.y más » |
Kapitall Blog (blog) |
Greece: A Slippery SlopeKapitall Blog (blog)Forest Laboratories Inc. (FRX, Earnings, Analysts, Financials): Develops, manufactures, and sells branded and generic forms of ethical drug products. Market cap at $9.09B, most recent closing price at $34.24.Beta at 0.69. Diluted TTM earnings per share ...y más » |
|
Weekly Stock Watch: April 30th ? May 4thMarket PlaygroundIronwood Pharmaceuticals (NASDAQ:IRWD) and partner Forest Laboratories, Inc. (NYSE:FRX) are developing Linaclotide as a direct competitor to Plecanatide. Plecanatide has thus far in development showed that it can treat both CIC and IBS-C without ...y más » |
|
Mylan Beats, Reaffirms Outlook - Analyst BlogNASDAQThe increase was mainly attributable to new product launches, which include the generic version of Forest Laboratories' ( FRX ) Lexapro. Third-party net sales from the EMEA market declined 13.7% to $335.6 million. The decline was mainly attributable to ...y más » |
|
Better Days Ahead For GlaxoSmithKlineSeeking AlphaLow to high estimates for pipeline contributions in 2017 vary by as much as 100% between analysts, with some analysts predicting a little over $1 billion for Relovair ]a new COPD drug that will presumably compete with drugs from Forest Labs (FRX) and ...y más » |
|
Anchura de la Página:
Imagen de Fondo: |
|  | |
|
|
